Outer membrane protein A (OmpA) from Shigella flexneri 2a: A promising subunit vaccine candidate

Vaccine

Volumn 31, Issue 36, 2013, Pages 3644-3650

  Pore, Debasis ^a,b   Chakrabarti, Manoj K ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

CD4+ T cells; Macrophages; Outer membrane protein A; Shigella flexneri 2a; Toll like receptors; Vaccine

Indexed keywords

EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN A; SHIGELLA VACCINE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 2;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELL SURFACE; CELLULAR IMMUNITY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHIGELLOSIS; TH1 CELL; UPREGULATION;

CD4+ T CELLS; MACROPHAGES; OUTER MEMBRANE PROTEIN A; SHIGELLA FLEXNERI 2A; TOLL-LIKE RECEPTORS; VACCINE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CROSS PROTECTION; DYSENTERY, BACILLARY; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; MICE; SHIGELLA FLEXNERI; TOLL-LIKE RECEPTOR 2;

EID: 84880932242     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.100     Document Type: Review

References (68)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swedlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77:651-666.
2. Ghosh A.R., Sehgal S.C. Existing status of shigellosis in Andaman. Existing status of shigellosis in Andaman & Nicobar Islands. Indian J Med Res 1996, 103:134-137.
3. Echeveriia P., Sethabutr O., Serichantelergs O., Lexomboon U., Tamura K. Shigella and enteroinvasive Escherichia coli infections in households of children with dysentery in Bangkok. J Infect Dis 1992, 16:144-147.
4. Fereccio C., Prado V., Ojeda A., Cayyazo M., et al. Epidemiologic pattern of acute diahhroea and endemic Shigella infections in children in a poor periurban setting in Santiago. Chile Am J Epidemiol 1991, 134:614-627.
5. Green M.S., Block C., Cohen D., Slater P. Four decades of shigellosis in Israel - the epidemiology of a growing public health problem. Rev Infect Dis 1991, 13:248-253.
6. Ashkenazi S., Levy I., Kazaronovski V., Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 2003, 51:427-429.
7. Anders K., Li A., Zhao C.R., Karlsson K., Minh N.B., Lindberg A.A. Safety and immunogenicity of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 1995, 13:88-89.
8. Coster T.S., Charles H.W., Lillian L., VanDeVerg A., Hartman A.B., Oaks E.V., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999, 67:3437-3443.
9. Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R., et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001, 69(3):1351-1357.
10. Ranallo R.T., Fonseka C.P., Cassels F., Srinivasan J., Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608 (pCFAI) and SC608 (pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 2005, 73(1):258-267.
11. Berry E.M., Wang J., Wu T., Davis T., Levine M.M. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 2006, 24(18):3728-3734.
12. Turbyfill K.R., Kaminski R.W., Oaks E.V. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. Vaccine 2008, 26(10):1353-1364.
13. Kaminski R.W., Turbyfill K.R., Chao C., Ching W.M., Oaks E.V. Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines. Clin Vaccine Immunol 2009, 16(4):574-586.
14. Formal S.B., Kent T.H., May H.C., Palmer A., Falkow S., LaBrec E.H. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol 1966, 92(1):17-22.
15. Mel D., Gangarosa E.J., Radovanovic M.L., Arsic B.L., Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull World Health Org 1971, 45(4):457-464.
16. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 2002, 70(4):2016-2021.
17. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 2004, 72(2):923-930.
18. Kotloff K.L., Noriega F.R., Samandari T., Sztein M.B., Losonsky G.A., Nataro J.P., et al. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 2000, 68:1034-1039.
19. Peng X., Ye X., Wang S. Identification of novel immunogenic proteins of Shigella flexneri 2a by proteomic methodologies. Vaccine 2004, 22:2750-2756.
20. Ying T., Wang H., Li M., Wang J., Shi Z., Feng E., et al. Immunoproteomics of outer membrane proteins and extracellular proteins of Shigella flexneri 2a 2457T. Proteomics 2005, 5:4777-4793.
21. Jennison A.V., Raquib R., Verma N.K. Immunoproteomic analysis of soluble and membrane proteins of Shigella flexneri 2a 2457T. World J Gastroenterol 2006, 12(41):6683-6688.
22. Torres A.G., Li Y., Tutt C.B., Xin L., Eaves-Pyles T., Soong L. Outer membrane protein A of Escherichia coli O157:H7 stimulates dendritic cell activation. Infect Immun 2006, 74:2676-2685.
23. Haeuw J.F., Rauly I., Zanna L., Libon C., Andreoni C., Nguyen T.N., et al. The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides. Eur J Biochem 1998, 255:446-454.
24. Goetsch L., Gonzalez A., Plotnicky-Gilquin H., Haeuw J.F., Aubry J.P., Beck A., et al. Targeting of nasal mucosa associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun 2001, 69:6434-6444.
25. Godefroy S., Corvaia N., Schmitt D., Aubry J.P., Bonnefoy J.Y., Jeannin P., et al. Outer membrane protein A (OmpA) activates human epidermal Langerhans cells. Eur J Cell Biol 2003, 82:193-200.
26. Jeannin P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Delneste Y., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 2000, 1:502-509.
27. Soulas C., Baussant T., Aubry J.P., Delneste Y., Barillat N., Caron G., et al. Outer membrane protein A (OmpA) binds to and activates human macrophages. J Immunol 2000, 165:2335-2340.
28. Jeannin P., Magistrelli G., Herbault N., Goetsch L., Godefroy S., Charbonnier P., et al. Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs. Eur J Immunol 2003, 33:326-333.
29. Mukhopadhaya A., Mahalanabis D., Khanam J., Chakrabarti M.K. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 2003, 21:3043-3050.
30. Mukhopadhaya A., Mahalanabis D., Chakrabarti M.K. Role of Shigella flexneri 2a 34kDa outer membrane protein in induction of protective immune response. Vaccine 2006, 24:6028-6036.
31. Pore D., Mahata N., Pal A., Chakrabarti M.K. Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS ONE 2011, 6(7):e22663.
32. Chang A., Kaur R., Michel L.V., Casey J.R., Pichichero M. Haemophilus influenzae vaccine candidate outer membrane protein P6 is not conserved in all strains. Human Vaccines 2011, 7(1):102-105.
33. Mes T.H., van Putten J.P. Positively selected codons in immune-exposed loops of the vaccine candidate OMP-P1 of Haemophilus influenzae. J Mol Evol 2007, 64(4):411-422.
34. Vandeputte-Rutten L., Bos M.P., Tommassen J., Gros P. Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem 2003, 278(27):24825-24830.
35. Steere A.C., Sikand V.K., Meurice F., Parenti D.L., Fikrig E., Schoen R.T., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998, 339:209-215.
36. Hewlett E.L. Pertussis: current concepts of pathogenesis and prevention. Pediatr Infect Dis J 1997, 16:S78-S84.
37. Delcour A.H. Structure and function of pore-forming beta-barrels from bacteria. J Mol Microbiol Biotechnol 2002, 4:1-10.
38. Sonntag I., Schwarz H., Hirota Y., Henning U. Cell envelope and shape of Escherichia coli: multiple mutants missing the outer membrane lipoprotein and other major outer membrane proteins. J Bacteriol 1978, 136:280-285.
39. Puohiniemi R., Karvonen M., Vuopio V.J., Muotiala A., Helander I.M., Sarvas M. A strong antibody response to the periplasmic C-terminal domain of the OmpA protein of Escherichia coli is produced by immunization with purified OmpA or with whole E. coli or Salmonella typhimurium bacteria. Infect Immun 1990, 58:1691-1696.
40. Schweizer M., Henning U. Action of a major outer cell envelope membrane protein in conjugation of Escherichia coli K-12. J Bacteriol 1977, 129:1651-1652.
41. Shin S., Lu G., Cai M., Kim K.S. Escherichia coli outer membrane protein A adheres to human brain microvascular endothelial cells. Biochem Biophys Res Commun 2005, 330:1199-1204.
42. Weiser J.N., Gotschlich E.C. Outer membrane protein A (OmpA) contributes to serum resistance and pathogenicity of Escherichia coli K-1. Infect Immun 1991, 59:2252.
43. Murphy T.F., Bartos L.C., Rice P.A., Nelson M.B., Duda K.C., Apicella M.A. Identification of a 16,600-dalton outer membrane protein on non-typable Haemophilus influenzae as a target for human serum bactericidal antibody. J Clin Invest 1986, 78:1020-1027.
44. Hughes E.E., Gilleland L.B., Gilleland H.E. Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa. Infect Immun 1992, 60:3497-3503.
45. Dumetz F., LaPatra S.E., Duchaud E., Claverol S., Henaff M.L. The Flavobacterium psychrophilum OmpA, an outer membrane glycoprotein, induces a humoral response in rainbow trout. J Appl Microbiol 2007, 103:1461-1470.
46. Koizumi N., Watanabe H. Molecular cloning and characterization of a novel leptospiral lipoprotein with OmpA domain. FEMS Microbiol Lett 2003, 226:215-219.
47. Crocquet-Valdes P.A., Diaz-Montero C.M., Feng H.M. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine 2001, 20:979-988.
48. Li H., Xiong X.P., Peng B., Xu C.X., Ye M.Z., Yang T.C., et al. Identification of broad cross-protective immunogens using heterogeneous antiserum-based immunoproteomic approach. J Proteome Res 2009, 8:4342-4349.
49. Brunham R.C., Plummer F.A., Stephens R.S. Bacterial antigenic variation, host immune response, and pathogen-host coevolution. Infect Immun 1993, 61:2273-2276.
50. Finlay B.B., Falkow S. Common themes in microbial pathogenicity revisited. Microbiol Mol Biol Rev 1997, 61:136-169.
51. Pore D., Chowdhury P., Mahata N., Pal A., Yamasaki S., Mahalanabis D., et al. Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a. Vaccine 2009, 27:5855-5864.
52. Mantis N.J., Rol N., Corthésy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunology 2011, 4:603-611.
53. Shtrichman R., Samuel C.E. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol 2001, 4(3):251-259.
54. Way S.S., Borczuk A.C., Dominitz R., Goldberg M.B. An essential role for gamma interferon in innate resistance to Shigella flexneri infection. Infect Immun 1998, 66:1342-1348.
55. Hoffmann J.A., Kafatos F.C., Janeway C.A., Ezekowitz R.A. Phylogenetic perspectives in innate immunity. Science 1999, 284:1313-1318.
56. Pore D., Mahata N., Pal A., Chakrabarti M.K. 34kDa MOMP of Shigella flexneri promotes TLR2 mediated macrophage activation with the engagement of NF-κB and p38 MAP kinase signaling. Mol Immunol 2010, 47(9):1739-1746.
57. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2009, 28:445-489.
58. Hieshima K., Ohtani H., Shibano M., Izawa D., Nakayama T., et al. CCL28 has dual roles in mucosal immunity as a chemokine with broad spectrum antimicrobial activity. J Immunol 2003, 170:1452-1461.
59. Standiford T.J., Kunkel S.L., Greenberger M.J., Laichalk L.L., Strieter R.M. Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996, 59:24-28.
60. Pore D., Mahata N., Chakrabarti M.K. Outer membrane protein A (OmpA) of Shigella flexneri 2a links innate and adaptive immunity in a TLR2 dependent manner and with the involvement of IL-12 and nitric oxide (NO). J Biol Chem 2012, 287(15):12589-12601.
61. Bogdan C., Rollinghoff M., Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000, 12:64-76.
62. Niedbala W., Wei X.Q., Piedrafita D., Xu D., Liew F.Y. Effects of nitric oxide on the induction and differentiation of Th1 cells. Eur J Immunol. 1999, 29(8):2498-2505.
63. + T cells. Nat Immunol 2002, 3:549-557.
64. Schulz E.G., Mariani L., Radbruch A., Hofer T. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity 2009, 30:673-683.
65. Barton G.M., Medzhitov R. Toll-like receptor signalling pathways. Science 2003, 300:1524-1525.
66. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 2006, 2(1):49-55.
67. Lahiri A., Das P., Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008, 26:6777-6783.
68. Pascale Jeannin P., Magistrelli G., Goetsch L., Haeuw J.F., Thieblemont N., Bonnefoy J.Y., et al. Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies. Vaccine 2002, 20:A23-A27.